Oseni Tablet, Film Coated
Product Images NDC 64764-253

This appears to be a list of recommended drug dosages and co-administration with Alogliptin, for substances that affect CYP enzymes which metabolize drugs. It also includes recommendations for Alogliptin dosages when administered with renally excreted drugs.*

This appears to be a list of different drugs and their dosages, as well as whether they are renally excreted or inhibitors of specific enzymes. It also includes different dosages of Alogliptin and information on their recommended use. No further information is available.*

The text appears to be presenting results of a clinical trial evaluating the efficacy of Alogiptn and Piogitazone in reducing ATC levels. The baseline mean ATC was 85 for all groups. The LS mean change in ATC is shown for different doses and combinations of the two drugs. The intent-to-treat population was included in the study. The final line indicates a significant reduction in ATC levels for the combination therapy compared to Alogiptn or Piogitazone alone.*

This is a description of a medication package containing film-coated tablets. The package has a National Drug Code of 64764-123-03, which should not be used if the seal over the battle is broken or missing. The dosage instructions are available in the package insert and the tablets contain 17 mg of liraglutide and 3 mg of dulaglutide. The package also contains pioglitazone tablets, which are to be kept in a container that is protected from moisture and humidity. The manufacturer is Takeda Pharmaceuticals America, Inc. with a location in Lexington, MA 02421.*

This text appears to be a set of instructions and cautionary advice related to a medication called Oseni (alogliptin and pioglitazone) tablets. It offers specific directives such as not accepting the product if the seal is broken or missing, the usual dosage, and how each individually contained tablet is composed of 17mg el berzoce and 49.59 mg ploglfazone. Most importantly, it offers advice on how to store the medicine and who distributed it (Takeda Pharmaceuticals America, Inc.), its NDC number, and how it should be labeled (Rx Only).*

Oseni tablets are a combination of 25mg of alogliptin and 15mg of pioglitazone hydrochloride, which is equivalent to 34mg of clogipin benzodiazepine for controlling blood sugar levels. This medication is packaged in a container of 60 tablets with dosage instructions provided in the package insert. The tablet bottle should be kept out of reach of children, stored at 26°C (77°F) and protected from moisture and humidity. Takeda Pharmaceuticals America, Inc. is the distributor of these tablets. The NDC number for Oseni tablets is 64764-251-03. It should only be dispensed with the medication guide and is prescription-only.*

This is a medication guide for Oseni (alogliptin and pioglitazone) tablets. It contains warnings not to accept the medication if the bottle opening is broken or missing, and to keep it out of reach of children. Each film-coated tablet contains 34mg of alogliptin benzoate equivalent to 25 mg of alogliptin and 49.59 mg pioglitazone hydrochloride equivalent to 45mg of pioglitazone. The medication should be stored at 25°C and protected from moisture and humidity. The guide also provides information about the distributor and dosage instructions.*

This is a description of a medication called Oseni, which is a tablet that contains 34mg of alogliptn berzodle and 33,06mg pioglitazone. It is used for treatment of diabetes. The user should not accept the medication if the bottle is broken or missing. The medication should be kept out of reach of children and the dosage instructions should be followed as provided in the package insert. The medication should be stored at 25°C (77°F), with the container being tightly closed and protected from moisture and humidity. The medication is distributed by Takeda Pharmaceuticals America, Inc. The NDC number is 64764-253-03 and the GTIN number is 0364764253035. There are 30 tablets in a dispenser and a medication guide is included.*